JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Cost of Revenue
JW (Cayman) Therapeutics Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Cost of Revenue
-¥85.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥1.9B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cost of Revenue
-¥1.1B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥35.2B
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-58%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥99.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Cost of Revenue?
Cost of Revenue
-85.6m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Cost of Revenue amounts to -85.6m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
2%
Over the last year, the Cost of Revenue growth was 2%.